TENX - Tenax Therapeutics, Inc. Common Stock -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Tenax Therapeutics, Inc. Common Stock
Tenax Therapeutics Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products for critical care patients and its products include Levosimendan and Oxycyte.
IPO Date: February 26, 1993
Sector: Healthcare
Industry: Biotech
Market Cap: $71.11M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.15 | 4.58%
Avg Daily Range (30 D): $0.51 | 8.19%
Avg Daily Range (90 D): $0.50 | 5.18%
Institutional Daily Volume
Avg Daily Volume: .83M
Avg Daily Volume (30 D): 8.19M
Avg Daily Volume (90 D): 3.45M
Trade Size
Avg Trade Size (Sh.): 405
Avg Trade Size (Sh.) (30 D): 311
Avg Trade Size (Sh.) (90 D): 216
Institutional Trades
Total Institutional Trades: 191
Avg Institutional Trade: $1.54M
Avg Institutional Trade (30 D): $1.57M
Avg Institutional Trade (90 D): $1.85M
Avg Institutional Trade Volume: .22M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.49M
Avg Closing Trade (30 D): $1.88M
Avg Closing Trade (90 D): $2.64M
Avg Closing Volume: 402.1K
 
News
Aug 29, 2026 @ 12:21 PM
Tenax Therapeutics Announces Presentation of Phase...
Source: Na
May 4, 2026 @ 11:00 AM
Tenax Therapeutics Appoints Timothy Healey, MBA as...
Source: Na
Aug 28, 2025 @ 11:00 AM
Tenax Therapeutics to Participate in the Cantor Gl...
Source: Tenax Therapeutics
Mar 19, 2025 @ 8:32 AM
Plastic Fencing Market to be Driven by Growing Res...
Source: The Insight Partners
Jan 31, 2025 @ 2:00 PM
Tenax Therapeutics to Participate in the Guggenhei...
Source: N/A
Financials
  TTM Q1 2026 Q4 2025
Basic EPS $-.35 $-.35 $-.38
Diluted EPS $-.35 $-.35 $-.38
Revenue $M $M $M
Gross Profit
Net Income / Loss $-17.8M $-15.72M $-15.54M
Operating Income / Loss $-18.78M $-16.57M $-16.45M
Cost of Revenue
Net Cash Flow $M $M $M
PE Ratio    
Splits
Jan 03, 2024 1:80
Jan 05, 2023 1:20
Feb 26, 2018 1:20
May 13, 2013 1:20